Plasma and cerebrospinal fluid levels of baclofen (lioresal®) at optimal therapeutic responses in spastic paresis

Knutsson, E; Lindblom, Ulf; Mårtensson, Anders

doi:10.1016/0022-510x(74)90163-4

Cited by 198 publications

(77 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The drug attenuated even maximal afterdischarge of hippocampal pyramidal cells at concentrations within the range of cerebrospinal fluid levels attained in patients treated for spasticity (Knutsson, Lindblom & MArtensson, 1974). This finding, along with previous reports of anticonvulsant efficacy in animals (Benedito & Leite, 1981;Meldrum, 1981), suggests that baclofen could be therapeutically valuable in seizure disorders that involve the hippocampus, such as temporal lobe epilepsy.…”

Section: Discussionsupporting

confidence: 70%

Anticonvulsant‐like actions of baclofen in the rat hippocampal slice

Ault

Nadler

1983

British J Pharmacology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 70%

Anticonvulsant‐like actions of baclofen in the rat hippocampal slice

Ault

Nadler

1983

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…Cortical spasticity applies to lesions within the brain; spinal spasticity is indicative of spinal pathology. Individuals with multiple sclerosis (MS) have routinely been placed in the spinal group due to the location of their lesions in the spinal cord, although they may possess brain lesions, decreased cognitive involvement, and more pronounced response to oral baclofen than those individuals with purely cortical spasticity, such as traumatic brain injury, cerebral palsy, and stroke (7,(12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

Intrathecal Baclofen for Spasticity Management: A Comparative Analysis of Spasticity of Spinal vs Cortical Origin

Saval

Chiodo

2010

The Journal of Spinal Cord Medicine

View full text Add to dashboard Cite

Background/Objective: To examine the differences in intrathecal baclofen management of individuals with spasticity of cortical vs spinal etiologies. Design: Retrospective chart review of 57 individuals with the diagnoses of severe cortical and spinal spasticity requiring an intrathecal baclofen pump. Methods: Parameters evaluated included daily dosage of medication required, flex vs simple continuous delivery modes, dosing changes, need for other local spasticity treatment, and catheter complications. Results: There were no statistically significant differences between individuals with cortical spasticity and spinal spasticity when comparing daily dosage, number of contacts, and mode of delivery. At 6 months, there was a statistically significant difference in dosing between individuals with multiple sclerosis and those without. Within groups, there was a significant difference in average daily dosing over 3 years. A significant difference was found comparing the use of botulinum toxin type A for upper extremity spasticity within the cortical group. Nine individuals had catheter complications. Conclusions: Cortical and spinal spasticity appear to parallel each other with no significant differences in daily dosing, dosing changes, and mode of delivery of intrathecal baclofen. This did not hold true at all time points for the multiple sclerosis subgroup. The significant difference noted within groups for daily dosing over the first 3 years challenges the notion of stable dosing over time. Focal injections of Botox/phenol in the upper extremities are an important adjunct therapy for patients with cortical spasticity, even after the placement of an intrathecal baclofen pump. Our complication rate was slightly lower than that reported in the literature.

show abstract

“…The pharmacokinetics and metabolism of baclofen have been previously investi gated (Faigle and Keberle, 1972;Knuttson, Lindblom and Martensson, 1974).…”

Section: Discussionmentioning

confidence: 99%